Last reviewed · How we verify
Cidofovir intravenous
Cidofovir is a nucleotide analog that inhibits viral DNA polymerase, preventing viral DNA replication in infected cells.
Cidofovir is a nucleotide analog that inhibits viral DNA polymerase, preventing viral DNA replication in infected cells. Used for Cytomegalovirus (CMV) retinitis in immunocompromised patients, CMV and other viral infections in immunocompromised populations.
At a glance
| Generic name | Cidofovir intravenous |
|---|---|
| Also known as | Vistide |
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Drug class | Nucleotide analog antiviral |
| Target | Viral DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Cidofovir is a cytosine nucleotide analog that is phosphorylated intracellularly and then incorporated into viral DNA, causing chain termination and inhibiting viral DNA polymerase. It has broad-spectrum activity against DNA viruses including cytomegalovirus (CMV), herpesviruses, and other viral pathogens. The drug is particularly useful for treating infections in immunocompromised patients where conventional antivirals may be ineffective or resistance has developed.
Approved indications
- Cytomegalovirus (CMV) retinitis in immunocompromised patients
- CMV and other viral infections in immunocompromised populations
Common side effects
- Nephrotoxicity / renal impairment
- Neutropenia
- Anemia
- Fever
- Nausea
- Ocular hypotony / vision loss
Key clinical trials
- A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT (PHASE3)
- A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection (PHASE2)
- Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia (PHASE2)
- Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) (PHASE3)
- Cidofovir in Renal Transplant Recipients With BKVN (PHASE1, PHASE2)
- Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis (PHASE4)
- A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cidofovir intravenous CI brief — competitive landscape report
- Cidofovir intravenous updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI